Agenus Inc (AGEN) 7.00 $AGEN Uptrend Call Worki
Post# of 273242
Posted On: 09/22/2016 11:15:15 PM
Agenus Inc (AGEN) 7.00 $AGEN
Uptrend Call Working As Antigenics Stock Rises 67.8% (AGEN)
Comtex SmarTrend(R) - Thu Sep 22, 12:42PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 4 months, Antigenics has returned 67.78% as of today's recent price of $7.01.
AGEN: 7.00 (-0.10)
Research Reports Initiation on Biotech Stocks -- Agenus, Nektar Therapeutics, GlobeImmune and Anthera Pharma
PR Newswire - Tue Sep 20, 4:45AM CDT
Ahead of today's trading session, Stock-Callers.com reviews the most recent performances of Agenus Inc. (NASDAQ: AGEN), Nektar Therapeutics (NASDAQ: NKTR), GlobeImmune Inc. (NASDAQ: GBIM), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). These companies belong to the Biotech industry, which is slowly gaining strength but remains down -17% YTD. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
AGEN: 7.00 (-0.10), ANTH: 3.14 (+0.06), NKTR: 19.52 (+0.37)
56.2% Return Seen to Date on SmarTrend Antigenics Call (AGEN)
Comtex SmarTrend(R) - Thu Sep 15, 12:16AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 4 months, Antigenics has returned 56.17% as of today's recent price of $6.52.
AGEN: 7.00 (-0.10)
GSK's candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
PR Newswire - Wed Sep 14, 4:38PM CDT
GSK (LSE/NYSE: GSK) today announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix(TM), showing 90% efficacy in adults aged 70 years and older that is maintained for at least four years1. The results were published in the New England Journal of Medicine (NEJM).
AGEN: 7.00 (-0.10), GSK: 43.58 (+0.37)
Antigenics Up 51.5% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Wed Sep 07, 12:49PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 51.50% as of today's recent price of $6.33.
AGEN: 7.00 (-0.10)
Agenus to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Sep 06, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12th at 2:10 p.m. Eastern Time. The conference will take place at the Lotte New York Palace Hotel in New York City.
AGEN: 7.00 (-0.10)
Uptrend Call Working As Antigenics Stock Rises 45.4% (AGEN)
Comtex SmarTrend(R) - Tue Aug 23, 12:43PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 45.39% as of today's recent price of $6.07.
AGEN: 7.00 (-0.10)
Why Agenus (AGEN) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Agenus (AGEN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
AGEN: 7.00 (-0.10)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 7.00 (-0.10), VNDA: 16.62 (+1.06), GNCA: 5.47 (+0.01), DNAI: 1.88 (unch)
Antigenics Has Returned 48.7% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Mon Aug 08, 12:44PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 48.74% as of today's recent price of $6.21.
AGEN: 7.00 (-0.10)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 7.00 (-0.10), BIIB: 314.81 (+2.81), ICPT: 170.47 (+1.69)
Will Agenus (AGEN) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:27AM CDT
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN)
AGEN: 7.00 (-0.10)
Geron (GERN) Posts Narrower-Than-Expected Loss in Q2
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 9:04AM CDT
Investor focus will remain on Geron's (GERN) progress with the development of imetelstat.
AGEN: 7.00 (-0.10), JNJ: 119.46 (+0.55), ANIP: 66.81 (+1.69), GERN: 2.22 (-0.03)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 7.00 (-0.10), ANIP: 66.81 (+1.69), AERI: 38.05 (-0.80), ANIK: 47.99 (+0.06)
Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:35AM CDT
Abeona Therapeutics Inc. (ABEO) was a big mover last session, as the company saw its shares rise around 6% on the day.
AGEN: 7.00 (-0.10), ABEO: 6.39 (-0.18)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 7.00 (-0.10), ANIP: 66.81 (+1.69), MRK: 63.02 (+0.32), NKTR: 19.52 (+0.37)
Uptrend Call Working As Antigenics Stock Rises 67.8% (AGEN)
Comtex SmarTrend(R) - Thu Sep 22, 12:42PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 4 months, Antigenics has returned 67.78% as of today's recent price of $7.01.
AGEN: 7.00 (-0.10)
Research Reports Initiation on Biotech Stocks -- Agenus, Nektar Therapeutics, GlobeImmune and Anthera Pharma
PR Newswire - Tue Sep 20, 4:45AM CDT
Ahead of today's trading session, Stock-Callers.com reviews the most recent performances of Agenus Inc. (NASDAQ: AGEN), Nektar Therapeutics (NASDAQ: NKTR), GlobeImmune Inc. (NASDAQ: GBIM), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). These companies belong to the Biotech industry, which is slowly gaining strength but remains down -17% YTD. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
AGEN: 7.00 (-0.10), ANTH: 3.14 (+0.06), NKTR: 19.52 (+0.37)
56.2% Return Seen to Date on SmarTrend Antigenics Call (AGEN)
Comtex SmarTrend(R) - Thu Sep 15, 12:16AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 4 months, Antigenics has returned 56.17% as of today's recent price of $6.52.
AGEN: 7.00 (-0.10)
GSK's candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
PR Newswire - Wed Sep 14, 4:38PM CDT
GSK (LSE/NYSE: GSK) today announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix(TM), showing 90% efficacy in adults aged 70 years and older that is maintained for at least four years1. The results were published in the New England Journal of Medicine (NEJM).
AGEN: 7.00 (-0.10), GSK: 43.58 (+0.37)
Antigenics Up 51.5% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Wed Sep 07, 12:49PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 51.50% as of today's recent price of $6.33.
AGEN: 7.00 (-0.10)
Agenus to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Sep 06, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12th at 2:10 p.m. Eastern Time. The conference will take place at the Lotte New York Palace Hotel in New York City.
AGEN: 7.00 (-0.10)
Uptrend Call Working As Antigenics Stock Rises 45.4% (AGEN)
Comtex SmarTrend(R) - Tue Aug 23, 12:43PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 45.39% as of today's recent price of $6.07.
AGEN: 7.00 (-0.10)
Why Agenus (AGEN) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Agenus (AGEN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
AGEN: 7.00 (-0.10)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 7.00 (-0.10), VNDA: 16.62 (+1.06), GNCA: 5.47 (+0.01), DNAI: 1.88 (unch)
Antigenics Has Returned 48.7% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Mon Aug 08, 12:44PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 48.74% as of today's recent price of $6.21.
AGEN: 7.00 (-0.10)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 7.00 (-0.10), BIIB: 314.81 (+2.81), ICPT: 170.47 (+1.69)
Will Agenus (AGEN) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:27AM CDT
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN)
AGEN: 7.00 (-0.10)
Geron (GERN) Posts Narrower-Than-Expected Loss in Q2
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 9:04AM CDT
Investor focus will remain on Geron's (GERN) progress with the development of imetelstat.
AGEN: 7.00 (-0.10), JNJ: 119.46 (+0.55), ANIP: 66.81 (+1.69), GERN: 2.22 (-0.03)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 7.00 (-0.10), ANIP: 66.81 (+1.69), AERI: 38.05 (-0.80), ANIK: 47.99 (+0.06)
Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:35AM CDT
Abeona Therapeutics Inc. (ABEO) was a big mover last session, as the company saw its shares rise around 6% on the day.
AGEN: 7.00 (-0.10), ABEO: 6.39 (-0.18)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 7.00 (-0.10), ANIP: 66.81 (+1.69), MRK: 63.02 (+0.32), NKTR: 19.52 (+0.37)
(0)
(0)Scroll down for more posts ▼